Tivozanib
Back to searchMolecule Structure
Scientific Name
Tivozanib
Description of the Drug
Tivozanib is a kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11800
http://www.drugbank.ca/drugs/DB11800
Brand Name(s)
Fotivda
Company Owner(s)
Aveo Pharmaceuticals Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | SINGLE PROTEIN | INHIBITOR | CHEMBL1913 |
| Vascular endothelial growth factor receptor | PROTEIN FAMILY | INHIBITOR | CHEMBL2095227 |
| Stem cell growth factor receptor | SINGLE PROTEIN | INHIBITOR | CHEMBL1936 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL172883 |
| Human Metabolome Database | HMDB0304847 |
| DrugBank | DB11800 |
| PubChem: Thomson Pharma | 14882223 |
| PubChem | 9911830 |
| LINCS | LSM-1005 |
| Nikkaji | J2.121.508B |
| PDBe | AV9 |
| BindingDB | 50331095 |
| DrugCentral | 5258 |
| ChemicalBook | CB82484655 |
| Guide to Pharmacology | 6058 |
| ChEBI | 91327 |
| ZINC | ZINC000001489430 |
